We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

1 hedge funds and large institutions have $425K invested in Revance Therapeutics, Inc. in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 170 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 173 → 1 (-172)

100% less capital invested

Capital invested by funds: $249M → $425K (-$249M)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 170

Holders
1
Holders Change
-172
Holders Change %
-99.42%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
170
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$26.1M
2
BCM
Beryl Capital Management
California
-$18M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$17.1M
4
OBAM
ODDO BHF Asset Management
France
-$15.5M
5
Fidelity International
Fidelity International
Bermuda
-$12.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
CL
76
CSS LLC
Illinois
– -$242K -79,519 Closed
AQR Capital Management
77
AQR Capital Management
Connecticut
– -$240K -78,988 Closed
Los Angeles Capital Management
78
Los Angeles Capital Management
California
– -$233K -76,725 Closed
ProShare Advisors
79
ProShare Advisors
Maryland
– -$229K -75,252 Closed
SG Americas Securities
80
SG Americas Securities
New York
– -$223K -73,488 Closed
WAM
81
Weiss Asset Management
Massachusetts
– -$199K -65,400 Closed
Invesco
82
Invesco
Georgia
– -$193K -63,537 Closed
Skandinaviska Enskilda Banken (SEB)
83
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$190K -62,041 Closed
FC
84
FORA Capital
Florida
– -$185K -60,868 Closed
MIM
85
MetLife Investment Management
New Jersey
– -$184K -60,514 Closed
Mirae Asset Global ETFs Holdings
86
Mirae Asset Global ETFs Holdings
Hong Kong
– -$181K -59,629 Closed
GI
87
GAMCO Investors
Connecticut
– -$178K -58,418 Closed
GC
88
Guggenheim Capital
Illinois
– -$177K -58,303 Closed
CF
89
Corebridge Financial
Texas
– -$157K -51,761 Closed
Wells Fargo
90
Wells Fargo
California
– -$150K -49,373 Closed
Commonwealth Equity Services
91
Commonwealth Equity Services
Massachusetts
– -$150K -49,333 Closed
IIM
92
INTECH Investment Management
Florida
– -$148K -48,563 Closed
RLWM
93
RF&L Wealth Management
Massachusetts
– -$146K -48,000 Closed
Manulife (Manufacturers Life Insurance)
94
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$120K -39,386 Closed
Simplex Trading
95
Simplex Trading
Illinois
– -$117K -38,598 Closed
CM
96
Caption Management
Oklahoma
– -$116K -38,290 Closed
Janus Henderson Group
97
Janus Henderson Group
United Kingdom
– -$116K -38,107 Closed
Zurich Cantonal Bank
98
Zurich Cantonal Bank
Switzerland
– -$100K -32,961 Closed
VOYA Investment Management
99
VOYA Investment Management
Georgia
– -$97.2K -31,975 Closed
New York State Common Retirement Fund
100
New York State Common Retirement Fund
New York
– -$95.3K -31,338 Closed
2 3
4
5 6

RVNC Hedge Fund Activity: Q1 2025 in Review

1 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2025, worth a combined $425K — down 100% from $249M a quarter earlier.

Sellers outnumbered buyers: 170 funds closed out of RVNC and 0 opened new positions — a net loss of 170 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $26.1M sold.

  • 1 institutional investor held Revance Therapeutics, Inc. (RVNC) as of Q1 2025, down from 173 in Q4 2024.
  • Funds reported $425K of Revance Therapeutics, Inc. stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Revance Therapeutics, Inc. positions in Q1 2025 and 170 closed out, a net change of -170 holders.
  • The largest Revance Therapeutics, Inc. seller in Q1 2025 was BlackRock, an estimated $26.1M sold.

Based on aggregated 13F filings for Q1 2025.